Genelux GNLX
NASDAQ GNLX
$1.96 -0.02 (-1.01%)
As of: Oct 23, 2026 · 2:55 PM EDT

Genelux (GNLX) Amortization of Deferred Charges (2022 - 2023)

Updated

Analysis

Genelux (GNLX) Amortization of Deferred Charges (2022 - 2023) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,127.89 Bn 1,096.47 Bn 19.71 Bn
2 Johnson & Johnson 635.11 Bn 554.97 Bn 17.30 Bn
3 AbbVie 504.69 Bn 477.80 Bn 12.70 Bn
4 Merck 358.24 Bn 312.62 Bn 12.21 Bn
5 Novartis Ag 290.13 Bn 254.12 Bn 11.24 Bn
6 Astrazeneca 265.05 Bn 238.74 Bn 12.86 Bn
7 Amgen 237.87 Bn 193.27 Bn 7.24 Bn
8 Gilead Sciences 194.91 Bn 169.11 Bn 6.22 Bn
9 Pfizer 171.28 Bn 117.93 Bn 10.94 Bn
10 Genelux 86.54 Mn 24.81 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2023 649,000.00
Dec 31, 2022 -87,000.00
Sep 30, 2022 49,000.00
Mar 31, 2022 49,000.00
API Access

Genelux Amortization of Deferred Charges API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=amortization-of-deferred-charges&ticker=GNLX&period=max&api_key=YOUR_API_KEY